Global Collaboration Action For Prevention And Treatment Of Lower Respiratory Tract Infections (LRTIs) In Sub-saharan Africa
HORIZON JU Research and Innovation Actions
Basic Information
- Identifier
- HORIZON-JU-GH-EDCTP3-2026-01-LRTI-02-two-stage
- Programme
- HORIZON-JU-GH-EDCTP3-2026-01-two-stage
- Programme Period
- 2021 - 2027
- Status
- Open (31094502)
- Opening Date
- January 14, 2026
- Deadline
- March 4, 2026
- Deadline Model
- two-stage
- Budget
- €33,900,000
- Min Grant Amount
- €8,475,000
- Max Grant Amount
- €8,475,000
- Expected Number of Grants
- 4
- Keywords
- HORIZON-JU-GH-EDCTP3-2026-01-LRTI-02-two-stageHORIZON-JU-GH-EDCTP3-2026-01-two-stageBacteriaChild healthClinical trialsDrug development, clinical phasesGlobal healthImmunologyInfectious diseasesMonoclonal antibodiesPoverty related diseasesPublic healthRespiratory systemsVaccinesViruses
Description
Expected impact
The actions funded under this topic should contribute to achieve the reduction of disease burden in SSA through increased international cooperation among researchers and funders, catalyse research synergies, and leverage resources and investment.
Proposals are expected to include the effective in-kind and/or financial contribution of contributing partners, in order to produce more meaningful and significant effects enhancing the impact of the related research activities.
Applicant consortium
The contributions from contributing partners should correspond to the amounts they have committed in the letter of endorsement requesting to become a contributing partner (Article 9 Council Regulation (EU) 2021/2085[1]). Their contributions can consist of financial contributions and/or in-kind contributions. Applicant contributing partners must submit a first draft of the endorsement letter to the Programme Office before the deadline for submission of the second-stage applications[2]. For details on the process on becoming a Global Health EDCTP3 contributing partner, please consult the Guide for contributing partners.
In case of in-kind contribution (even combined with financial contribution), contributing partners become a part of the applicant consortium and participate in the project, as appropriate i.e. as beneficiaries or affiliated entities in the meaning of Article 8 of the Horizon Europe model grant agreement. Also, Global Health EDCTP3 contributing partners can be a country, an international organisation or any public or private legal entity, other than the Global Health EDCTP3 members or their constituent or affiliated entities (please consult the Guide for contributing partners.).
Expected Outcome:Background
Lower respiratory tract infections (LRTIs) are a leading cause of morbidity and mortality in Sub-Saharan Africa (SSA), particularly among children under five years, the elderly, and immunocompromised individuals. LRTIs is among the top four causes of mortality despite the existence of vaccines against many of their aetiologies suggesting that deaths are largely preventable.
From a prevention perspective, numerous areas require improvement. Awareness about preventive measures such as improved sanitation, better air quality, and reducing indoor air pollution are essential, especially in children. Other vital components for combating the spread of LRTIs are public health education campaigns focusing on hygiene practices, breastfeeding as well as vaccination and the importance of early medical intervention.
Vaccines against pneumococcal disease, influenza, and respiratory syncytial virus (RSV) have proven effective in reducing LRTI-related hospitalizations and deaths in other regions in the world. However, access to vaccines and coverage of these vaccines in SSA is insufficient due to financial and logistical barriers. A single-dose monoclonal antibody (mAb) that provides season-long protection against RSV was approved in EU in 2022. However, several barriers preclude the successful delivery of the mAb in LMICs, including low awareness and accessibility of the mAbs, including the costs of mAbs. The assessment of barriers—financial, logistical, and other—remains a fundamental challenge in achieving optimal vaccine coverage in SSA.
Treatments such as antivirals and low-cost monoclonal antibodies can prevent death once an individual is infected, yet accessibility is to be improved for those in need. To better target the treatment avoiding overuse of antibiotics, it is also important to have rapid diagnostics available, accessible and affordable.
Addressing LRTIs in the region requires targeted multifaceted strategies that consider local challenges such as limited healthcare access, high disease burden other infectious diseases like HIV and malaria, and antimicrobial resistance. Improving access to quality healthcare is critical. Many rural areas in SSA face shortages in healthcare workers and medical supplies, making timely diagnosis and treatment of LRTIs challenging. Strengthening healthcare systems, increasing the availability of essential medications (such as antibiotics for bacterial infections and oxygen therapy for severe cases), and ensuring consistent access to the appropriate vaccines.
Country-level strategies and work plans, coordination of the interventions, critical partners engagement, and promotion of the innovations to overcome the barriers to service delivery are recommended by the Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD) to governments and partners in order to reduce the mortality from LRTIs (especially in children) and its incidence, following the Protect-Prevent-Treat strategy.
Expected Outcome
The proposals submitted under this topic should aim to deliver results that are directed, tailored towards and contributing to strengthening the capacity of SSA health actors to address LRTIs, associated complications and barriers to effective management.
In addition, proposals are also expected to lead to:
- improved LRTI-related outcomes, including mortality and morbidity in SSA and/or
- increased access to LRTI interventions in SSA.
Scope
Proposals submitted under this topic should carry out late-stage clinical studies (Phase IIb and after) advancing prevention and treatment of pathogens related to Lower respiratory tract infection (LRTI) by evaluating the safety, immunogenicity, efficacy and/or effectiveness of approved or novel preventive or therapeutic candidates targeting individuals in SSA.
The proposals submitted under this topic should address at least one of the following points:
- Obtain evidence of immunogenicity, efficacy, safety or clinical utility on new or existing preventive measures against LRTI pathogens listed below, or
- Obtain evidence of efficacy, safety or clinical utility on new or existing treatment measures against LRTI pathogens listed below.
In addition, the proposals submitted under this topic should include at least one of the following:
- Obtain evidence on new or existing preventive health solutions against LRTI for children (including maternal vaccination).
- Improvement of preventive and/or treatment measure’s coverage, access, scaling-up and/or availability.
- Implementation of existing intervention with demonstrated efficacy and safety in other regions, with generation of data on real-world effectiveness and cost-effectiveness.
- Generate clinical data on host-strengthening interventions (non-specific effects of live attenuated vaccines, pre/probiotics, and/or other non-pharmaceutical interventions).
Applicants are encouraged to focus on interventions that could become available to patients as soon as possible, as assets in phase III and interventions already approved in EU/US.
Clinical studies and implementation research if any, of interventions already approved in EU and/or US should be designed fit-for-purpose, generating the data as needed to ensure the implementation of interventions in SSA.
Pathogens in scope of the topic are: S. pneumoniae, H. influenzae, S. aureus, and K. pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumoniae, human respiratory syncytial virus (RSV), adenovirus, rhinovirus/enterovirus, influenza A/B, human parainfluenza viruses, and human metapneumovirus. Pathogens/disease that are considered out of scope are Mycobacterium tuberculosis/Tuberculosis, Cytomegalovirus (CMV), human coronaviruses and fungi.
Prophylactic vaccines, monoclonal antibodies and antiviral therapeutics (excluding antibiotics) are in scope. Proposals evaluating monoclonal antibodies should aim to increase accessibility by reducing the cost of production enabling a lower purchase price.
Implementation research to enable global access of the interventions by addressing cost effectiveness analysis and/or assessing barriers for access and health system integration, is in scope. In addition, proposals including implementation research are encouraged to consider rural and remote areas as well as informal urban settlements.
Sex and gender differences and the effects of age should be duly taken into account when relevant. For Phase III studies, applicants are encouraged to ensure adequate statistical power for sex/gender- and age-specific analyses as relevant.
Activities which are encouraged to be included in the proposals are: generating evidence on new or existing preventive health solutions against LRTI targeting specifically children, activities that lead to the improvement of the uptake, access, scaling-up and/or availability of the health solutions, implementation of existing intervention with demonstrated efficacy and safety in other regions, with generation of data on real-world effectiveness and cost-effectiveness, activities that combines therapeutics with the improvement of oxygen and ventilation support when relevant, capacity building and training activities focusing on effective use of treatment and prevention strategies.
Development of antibiotics and diagnostics are considered out of scope. However, use of diagnostics as standard of care addressing differential diagnosis is permissible.
Preclinical studies are considered out of scope of the topic.
However, preparatory activities conducted during the preclinical phase can be considered in scope if they enable the conduct of the clinical study/ies in scope (these activities include but are not limited to protocol writing, development/evaluation of laboratory tests, CMC related activities, etc.).
The purpose of this topic is to fund a varied portfolio of LRTI related projects. In addition, it is highly important to implement solutions as soon as possible, in particularly for health solutions which have shown improved health outcomes in other regions of the world as EU and US. The granting authority will therefore base its funding decision relevant to this topic on the ranking of the proposals taking into account diversity of the respective diseases targeted in the proposals that are graded above the threshold as well as taking into account late-stage proposals, for proposals that are graded above the threshold.
For all Global Collaboration Actions such as this topic, proposals submitted are expected to leverage financial and/or in-kind contribution from contributing partners. Proposals should define the activities of their project in its entirety, including details of the component(s) for which Global Health EDCTP3 funding is requested and the component(s) that are to be financed by contributing partners. Each contribution should be well described and budgeted in each proposal, so that the activities and related costs that are covered by the in-kind or financial contribution(s) are clearly identified.
The applicants are encouraged to consider the latest innovations and advances in the clinical trial design and research methods in order to evaluate promising interventions allowing shorter development timings. Applicants are also encouraged to follow the WHO Guidance for best practices for clinical trials.
Where possible, collaboration and coordination with the AU-EU Health Partnership’s Manufacturing and Access to Vaccines, medicines and health technologies (MAV+) hub or similar African initiatives is encouraged. Applicants could show, for example, willingness to enter into technology transfer agreements with African counterparts - including the provision of patents, technical knowledge and know-how -, or early engagement with regulators or with African manufacturers to support the translation into affordable products adapted to the regional market.
Applicants are reminded of the expectation that proposals should come from research consortia with a strong representation of institutions and researchers from SSA countries, including involvement of Franco/Lusophone countries, if possible. Applicants are also reminded of the expectation of reaching out to organisations in countries with relatively lower research capacities.
Proposals should clearly describe the desired Target Product Profile. Applicants need to concisely describe any prior relevant research findings and explain how the proposal builds on available data (including data generated in scope of earlier EDCTP programmes if available). Full details of the development milestones, including specific go/no-go criteria for the implementation of the proposed clinical trial(s) must be included, as well as specific plans for the subsequent regulatory approval process, which should aim at obtaining relevant market authorisation and an access strategy that will allow patients in low-resource settings to access the final product.
Proposals should engage communities and relevant stakeholders, most notably (local) key opinion leaders, researchers, health care professionals, policy makers, public health authorities and end-users. Applicants should provide methodologies for translating research findings into public health practice and policy guidelines and are encouraged to follow guidance provided in the EDCTP Knowledge Hub Research into Policy Toolkit.
[2] The Global Health EDCTP3 Programme Office will ask the applicant contributing partner to revise the letter in case it significantly departs from the template letter published on the Global Health EDCTP3 website or is missing any compulsory elements. The final decision as to acceptance or rejection of a new contributing partner rests with the Global Health EDCTP3 Governing Board.
Eligibility & Conditions
General conditions
1. Admissibility Conditions: Proposal page limit and layout
2. Eligible Countries
described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligible Conditions
The conditions are described in General Annex B except for the specific conditions for the Global Health EDCTP3 JU funding as regards entities eligible for funding and consortium composition, the specific rule for countries where the coordinator may be established and the obligation to designate a scientific project leader as below.
Specific conditions replacing the relevant sections in General Annex B to the Horizon Europe Work Programmes
A. Entities eligible for funding
This section applies to both Research and Innovation Actions (RIA) and Coordination and Support Actions (CSA).
To become a beneficiary, legal entities must be eligible for funding. To be eligible for funding, applicants must be established in one of the following countries:
- The Member States of the European Union, including their outermost regions: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden;
- The Overseas Countries and Territories (OCTs) linked to the Member States: Aruba (NL), Bonaire (NL), Curação (NL), French Polynesia (FR), French Southern and Antarctic Territories (FR), Greenland (DK), New Caledonia (FR), Saba (NL), Saint Barthélemy (FR), Sint Eustatius (NL), Sint Maarten (NL), St. Pierre and Miquelon (FR), Wallis and Futuna Islands (FR);
- Countries associated to Horizon Europe[[The list is correct at the time of adoption of this work programme. Please see the Horizon Europe List of Participating Countries on the Funding & Tenders Portal for up-to-date information on the current list and on the position for Associated Countries: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratom_en.pdf]]: Albania, Armenia, Bosnia and Herzegovina, Canada (associated to Pillar II 'Global Challenges and European Industrial Competitiveness', including for the institutionalised European partnerships, and for award procedures implementing Union budget for the year 2024 and onwards), Faroe Islands, Georgia, Iceland, Israel, Kosovo[[This designation is without prejudice to positions on status and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.]], Moldova, Montenegro, New Zealand (associated to Pillar II 'Global Challenges and European Industrial Competitiveness' as from the Work Programmes 2023 onwards, including for the institutionalised European partnerships), North Macedonia, Norway, Serbia, Republic of Korea (Pillar II only), Switzerland, Tunisia, Turkey, Ukraine, United Kingdom;
- Until association agreements start producing legal effects either through provisional application or their entry into force, transitional arrangements apply. The transitional arrangements apply, at the time of the adoption of this Work Programme, with regard to the following countries and legal entities established in these countries, with which association negotiations are being processed or where association is imminent): Egypt, Morocco, .
- The following countries which are constituent states of the EDCTP Association[[The list is correct at the time of adoption of this work programme. For an update, please check the EDCTP Association website www.edctp.org.]]: Benin, Burkina Faso, Burundi, Cameroon, Côte d’Ivoire, Democratic Republic of the Congo, Ethiopia, Eswatini, Gabon, The Gambia, Ghana, Guinea-Bissau, Guinea-Conakry, Kenya, Liberia, Malawi, Mali, Mozambique, Namibia, Niger, Nigeria, Republic of the Congo, Rwanda, Senegal, Sierra Leone, Somalia, South Africa, Tanzania, Uganda, Zambia, Zimbabwe.
Legal entities which are established in countries not listed above (including in low-and middle-income countries that are not members of the EDCTP Association) will be eligible for funding if provided for in the specific call topic conditions, or if their participation is considered essential for implementing the action by the granting authority.
B. Consortium composition
Unless otherwise provided for in the specific call conditions, for all actions, due to the policy objectives of Global Health EDCTP3, legal entities forming a consortium are eligible to participate in actions under the programme provided that the consortium includes as beneficiaries:
- At least three legal entities independent from each other and each established in a different country, where legal entities are eligible to receive funding;
- At least one independent legal entity established in a Member State, or in an associated country to Horizon Europe that is a member of the EDCTP Association; and
- At least one independent legal entity established in a sub-Saharan African country that is a member of the EDCTP Association.
This condition applies to both Research and Innovation Actions (RIA) and Coordination and Support Actions (CSA).
For the two CSA (2) topics under call HORIZON-JU-GH-EDCTP3-2026-03 in case the applicant consortia opt for including the EDCTP Association as coordinator, the EDCTP Association must not be counted as one of the three independent legal entities necessary to ensure the eligibility of the consortium composition.
Specific cases:
Affiliated entities — Affiliated entities are eligible for funding under the same conditions as beneficiaries.
Associated partners — Entities not eligible for funding and therefore not able to participate as beneficiaries or affiliated entities (i.e. entities which participate in the action without signing the grant agreement, and without the right to charge costs or claim contributions) are allowed, subject to any conditions regarding associated partners set out in the specific call conditions.
International organisations – International European research organisations are eligible to receive funding. Other international organisations are not eligible to receive funding unless their participation is considered essential for implementing the action by the granting authority. International organisations with headquarters in a Member State or associated country are eligible to receive funding when provided for in the specific call conditions.
Specific rules regarding legal entities that may be the coordinator of an indirect action
In accordance with Article 110(2) of the Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe[[Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014, p. 17–119.]], where entities established in a third country without an agreement to protect the financial interests of the Union participate with funding in an indirect action, the coordinator of the indirect action must be established in a Member State or associated country, or South Africa.
Scientific project leader
If the coordinator is not established in a country in SSA (please see previous paragraph), the designation of a scientific project leader established in a SSA country member of the EDCTP Association with the roles as described below is mandatory. A work package on ‘scientific project leadership’ must be included in the proposals and budget needs to be provided for this activity. The scientific project leader oversees the project scientific governance and leadership. For this purpose, proposals must include a work package where the details of scientific project leadership are laid down. The scientific project leader should indicatively perform the following tasks:
- During the call for proposals and selection process, coordinate meetings on and drafting of the full project proposal.
- Work with the coordinator and other beneficiaries on the drafting and negotiation of the consortium agreement and other legal agreements among the beneficiaries.
- Act as the key contact point for the Global Health EDCTP3 JU regarding all scientific action governance issues, steer and provide oversight in the development of the scientific actions, without prejudice to the tasks entrusted directly to the coordinator as per the Model Grant Agreement.
- Support and collaborate with the coordinator on its monitoring activities and the adoption of appropriate internal measures, to ensure that beneficiaries are fulfilling their obligations regarding budget, timeline, deliverables, and scientific quality.
- Review the action’s deliverables and reports before their submission by the coordinator.
- Lead the work packages(s) related to the tasks of scientific project leadership.
Annex 1 to the grant agreement and the consortium agreement should address the relationship of the scientific project leader with the coordinator regarding their respective tasks, for example sharing of the information received from or sent to Global Health EDCTP3 on all issues of interest for the proper scientific management of the action.
described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
are described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
Specific conditions related to Scores and weighting
Replacing the scores and weighting section in General Annex D to the Horizon Europe Work Programmes as regards second stage of two-stage evaluations, for Research and Innovation Actions (RIA). Evaluation scores will be awarded for the criteria, and not for the different aspects listed in the table. For full applications, each criterion will be scored out of 5. The threshold for individual criteria 1 (Excellence) and 2 (Impact) will be 4 and for criterion 3 (Quality and Efficiency of the implementation) will be 3. The overall threshold, applying to the sum of the three individual scores, will be 12.
Proposals that pass the individual threshold and the overall threshold will be considered for funding, within the limits of the available call budget. Other proposals will be rejected.
Nota bene: for the CSAs and the first stage of the two-stage evaluation of RIAs, the scores and weighting as indicated in Annex D of the General Annexes of the Horizon Europe work programme 2023/2025 apply.
In addition to the aspects of award criteria included in General Annex D, the following aspects are taken into consideration during the evaluation of second-stage proposals:
For the ‘impact’ criterion: Production of meaningful and significant effects enhancing the impact of the relevant research activities via the inclusion of effective in-kind and/or financial contribution of contributing partners.
For the ‘quality and efficiency of the implementation’ criterion: Leveraging of financial and/or in-kind contributions from contributing partners that are equal or greater than the requested JU contribution, in order to ensure the necessary resources and effort for the action.
are described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
Implementing the provision on affordable access as defined in Article 114 of the Council Regulation 2021/2085[[Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014, p. 17.]], grants awarded under this topic will have to include in their Plan for the exploitation and dissemination of results including communication activities to be submitted during the project as a deliverable also the following:
Access plan
Participants must include in their Plan for the exploitation and dissemination of results[[For more information on the Plan for the exploitation and dissemination of results, please consult the General Annexes of Horizon Europe Work Programmes.]] an appropriate and proportionate access plan that demonstrates their strategies to ensure that the products and services that they develop based or partly based on the results of clinical studies undertaken by their project are affordable, available and accessible to the public (market and end-users) at fair and reasonable conditions. This covers registration targets, plans to meet demand, flexible approaches to IP, engagement with regulators and manufacturers where relevant and other strategies that reflect ability to pay and ensures that economic barriers to access are low. In addition, participants should add, if relevant, as part of the plan, an outline on how to achieve the optimal use of an intervention including, for example, how to avoid irrational use, overuse or abuse (e.g. antimicrobials).
The plan is to be submitted with the second-stage proposal. In addition to any updates during the project, a final version of the Plan for the exploitation and dissemination of results including the above access plan, must also be submitted with the final report of the project.
Also in line with Article 114 of the Council Regulation 2021/2085[[Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014]], participants will be subject to the following additional exploitation obligations:
- Participants must – up to four years after the end of the action (see Data Sheet, Point 1) – use their best efforts to ensure that resulting health technologies and services will be broadly available and accessible, as soon as possible and at fair and reasonable conditions. In this respect, if, despite a participants’ best efforts, the results are not exploited within one year after the end of the action, participants must (unless otherwise agreed in writing with the granting authority) use the Horizon Results Platform to find interested parties to exploit the results.
- In case the participants cannot fulfil the preceding obligation, the participants must (if requested by the granting authority) grant non-exclusive licences - under fair and reasonable conditions - to their results to legal entities that commit to rapidly and broadly exploiting the resulting health technologies and services and ensure that they are broadly available and accessible, as soon as possible and at fair and reasonable conditions.
- In case of transfer of the ownership or licensing of results, participants must pass on such additional exploitation obligations to the legal entities exploiting the results.
- For up to four years after the action (see Data Sheet, Point 1), the funding body must be informed every year about the status of the development of the product and any other exploitation of the results through an annual report that is due on each anniversary of the end of the grant agreement.
described in Annex G of the Work Programme General Annexes.
Specific conditions
JU right to object to transfer/exclusive licensing
Global Health EDCTP3 may, up to four (4) years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5 of the Model Grant Agreement. In addition, in accordance with Article 24(3) of Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe[[Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014, p. 17.]] and the Model Grant Agreement, the right to object applies also to participants that have not received funding from the JU.
Information sharing regarding the proposals and the evaluation results
Applicants should be aware that the following information regarding their proposals may be shared with the members of the JU Committee of the EDCTP Association:
- Following eligibility check of the applications: aggregated country level data i.e. number of applicants, funding requested, organisation type;
- For successful proposals, following Global Health EDCTP3 Governing Board decision on the call evaluation results: number; acronym; title; duration; role; country; legal name; PIC; legal type; total cost; requested JU contribution;
- Regarding project information following Grant Agreement (GA) signature: signature date of the GA; number, acronym, title, and duration of projects; role, country, legal name, PIC, legal type, URL, total cost, requested JU contribution, FC received, FC given, and IKOP of participants;
- Under specific conditions and following Global Health EDCTP3 Governing Board approval of the request of EDCTP Association, for proposals on the reserve list and unsuccessful proposals: number; acronym; title; duration; role; country; legal name; PIC; legal type; total cost; requested JU contribution.
Access to information and involvement of contributing partners
Evaluation
To promote transparency and accountability, Global Health EDCTP3 may invite any contributing partners providing financial contributions under a certain topic to propose one representative as observer to participate in the evaluation process under confidentiality safeguards. This possibility does not apply to contributing partners that are part of a consortium submitting a proposal under the relevant topic.
Documents and information
By applying under any topic, participants consent that the JU reserves the right to share information and documents relevant to their application and where applicable their grant agreement and its implementation with contributing partners as identified and providing financial contributions under the relevant topic. This information and documentation will only be shared under confidentiality safeguards for policy and monitoring purposes. They include:
- Project proposals;
- Project results;
- Project reports;
- Project deliverables;
- Audit reports.
Global Health EDCTP3 may consult the relevant contributing partners for the purpose of assessing the project reports and deliverables.
Other requirements
For all projects under this topic, if the coordinator is not from a country in SSA, the designation of a scientific project leader with the roles as described in the introduction is mandatory. A work package on ‘scientific project leadership’ must be included in the proposals and budget needs to be provided for this activity.
Application and evaluation forms and model grant agreement (MGA):
Application form templates — the application form specific to this call is available in the Submission System
Note: despite blind evaluation being mentioned in the standard application form for stage 1 proposals of the two-stage calls available in the Funding and Tenders Portal (at the stage of adoption of this Work Programme), please note that the calls included in this WP are not part of the ‘blind evaluation pilot’, therefore no anonymisation is required for stage 1 proposals of the two-stage calls.
Standard application form (HE RIA IA Stage 1)
Evaluation form templates — will be used with the necessary adaptations
Standard evaluation form (HE RIA, IA and CSA Stage 1)
Guidance
Model Grant Agreements (MGA)
Call-specific instructions
Additional documents:
HE Main Work Programme 2026-2027 – 1. General Introduction
HE Main Work Programme 2026-2027 – 4. Health
HE Main Work Programme 2026-2027 – 15. General Annexes
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Frequently Asked Questions About Global Collaboration Action For Prevention And Treatment Of Lower Respiratory Tract Infections (LRTIs) In Sub-saharan Africa
Support & Resources
Online Manual is your guide on the procedures from proposal submission to managing your grant.
Horizon Europe Programme Guide contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.
Funding & Tenders Portal FAQ – find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.
Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.
National Contact Points (NCPs) – get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (‘third-countries’).
Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.
IT Helpdesk – contact the Funding & Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.
European IPR Helpdesk assists you on intellectual property issues.
CEN-CENELEC Research Helpdesk and ETSI Research Helpdesk – the European Standards Organisations advise you how to tackle standardisation in your project proposal.
The European Charter for Researchers and the Code of Conduct for their recruitment – consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.
Partner Search help you find a partner organisation for your proposal.